<http://schema.org/description>
"Sanofi  announced this week that the Food and Drug Administration began to review the company&amp;#039;s once-daily type 2 diabetes injectable lixisenatide. The GLP-1 agonist would join a crowded"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.aol.com/article/2013/02/20/sanofis-glp-1-accepted-for-review-by-fda/20470232/?gen=1>